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Background: No effective therapy is currently available for the diffuse stage of
bronchioloalveolar carcinoma.
Objective: We tested the hypothesis that total lung replacement with standard lung
transplantation techniques would provide curative therapy.
Methods: Nine patients aged 31 to 58 years with bronchioloalveolar carcinoma were
entered in the study. Five patients initially had bilateral diffuse tumor. Four patients
had recurrence in the contralateral lung after pulmonary resection.
Results: Between 1993 and 1998, all 9 patients underwent transplantation (2
single-lung and 7 bilateral transplants, 1 reoperative single-lung transplant, and 1
reoperative bilateral transplant). Two patients had mediastinal node metastasis
(level 7) at the time of transplantation, and 1 of these had a frankly invasive
adenocarcinoma. Of the 8 patients with pure bronchioloalveolar carcinoma, 6 had
recurrent pulmonary tumor after transplantation. In 2 of these patients the tumor was
localized and could be resected with left lower lobectomy in one case and left
pneumonectomy in the other. One is alive 89 months after transplantation; the other
died 82 months after transplantation. Four other patients had a diffuse pattern of
pulmonary recurrence. Two died of progressive pulmonary failure; 1 of these had
retransplantation with recurrence. A third patient died of cerebral edema shortly
after bilateral retransplantation. The other patient is alive with recurrence 39 months
after transplantation and has bronchiolitis obliterans. Two patients without recur-
rence are well with unrestricted performance levels 87 and 76 months after trans-
plantation.
Conclusions: Transplantation produces a powerful palliative outcome in patients
with advanced bronchioloalveolar carcinoma, but the recurrence rate is high. Trans-
plantation for this indication remains controversial.
Bronchioloalveolar carcinoma (BAC) comprises about 3% of themalignant tumors of the lung. It is characterized as a subset ofpulmonary adenocarcinoma in which well-differentiated tumorcells grow along the walls of alveoli with preservation of theunderlying lung architecture. The more malignant histologic fea-tures of adenocarcinoma (severe cytologic pleomorphism, solid
tumors that destroy the lung architecture, and invasive fibroblastic stroma) are
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absent. BAC usually is seen as a localized lesion, and
surgical resection yields good long-term survival.1,2 When
the disease is diffuse and bilateral, however, survival be-
yond 2 years from the time of diagnosis is uncommon.3-5
Disability and death are caused by pulmonary failure from
tumor replacement of functioning lung, usually before re-
gional or distant metastases occur. Effective treatment pro-
grams with radiotherapy and chemotherapy have not been
established. We tested the hypothesis that total lung re-
moval and replacement with standard single- and double-
lung transplantation techniques could be curative for the
diffuse form of BAC when confined to the lung.
Methods
Before lung transplantation, the histologic data from previous
pulmonary resections and biopsy specimens of the original tumor
were reviewed. Open lung biopsies were repeated as needed. At
the time of open lung biopsy, a substantial pulmonary resection
was required to ensure sampling of the central portion of the
tumor. Mediastinal lymph nodes not accessible to mediastinoscopy
were sampled at the time of open lung biopsy. All patients under-
went bone scan, brain scan, computed tomographic scans of the
thorax and upper abdomen, liver ultrasonography, and mediasti-
noscopy to exclude evidence of distant or regional metastasis. All
patients underwent a standard pulmonary transplant evaluation in
addition to these studies. All study patients underwent transplan-
tation between 1993 and 1998.
The study patients and their previous therapies are summarized
in Table 1. Five patients were first seen with bilateral diffuse
tumors that were unsuitable for localized pulmonary resection.
Four patients had recurrence in the contralateral lung after pulmo-
nary resection. The 2 patients with previous pneumonectomy un-
derwent contralateral single-lung transplantation with cardiopul-
monary bypass. The other 7 patients underwent bilateral sequential
lung transplantation. Five of the 7 required cardiopulmonary by-
pass because of the inability to tolerate single-lung ventilation. The
waiting times for lung transplantation are indicated in Figure 1.
Immunosuppression consisted of cyclosporine (INN ciclosporin),
azathioprine, and prednisone. No induction cytolytic therapy was
used. Our standard follow-up care was given, including surveil-
lance transbronchial biopsies at 3-month intervals during the first
year, followed thereafter at 6-month intervals. Annual computed
tomographic scans of the thorax and upper abdomen were added
for tumor surveillance.
Survival curves were performed with the method of Kaplan and
Meier.6 Follow-up was through May 31, 2001. This study protocol
was approved by the institutional review board, and study patients
gave informed consent.
Results
The outcomes after transplantation are summarized in Table
2. After pathologic examination of the surgical specimens, 8
of the 9 patients were found to have true BAC. Three had
the mucinous subtype (cases 4, 5, and 9) and the other 5 had
the nonmucinous subtype. The tumor extensively involved
the lung parenchyma, but all margins were free of tumor.
All hilar and mediastinal lymph nodes were free of tumor
except in 2 patients (cases 7 and 9), who had metastasis to
level 7 lymph nodes. Case 9 had early diffuse recurrence at
9 months and died of cerebral edema 10 days after retrans-
plantation. The second patient (case 7) had an invasive
adenocarcinoma with a prominent bronchioloalveolar pat-
tern and metastasis to subcarinal lymph nodes (level 7). This
patient is not included in the survival analysis in Figure 2.
Tumor recurrences in the transplanted lungs have oc-
curred in 6 of the 8 patients with true BAC. Two patterns of
Figure 1. Waiting time for transplantation in days. Cases 5 and 9
underwent retransplantation.
TABLE 1. Lung transplantation for BAC
Case Age (y) Sex Previous therapy Transplant procedure
1 41 F Right lower lobectomy Bilateral with CPB
2 34 F Left pneumonectomy Right single with CPB
3 50 M Right upper and right lower lobectomies, chemotherapy Bilateral with CPB
4 53 M None Bilateral with CPB
5 48 F Right pneumonectomy, radiation therapy Left single with CPB
6 41 F None Bilateral with CPB
7* 50 M Chemotherapy Bilateral
8 58 F None Bilateral with CPB
9 31 F Chemotherapy Bilateral
CPB, Cardiopulmonary bypass.
*Stage IV adenocarcinoma.
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recurrence were noted: (1) one or more isolated lesions and
(2) many small nodular lesions throughout the lung paren-
chyma. In 2 patients, secondary pulmonary resections for
localized recurrent tumor were accomplished at 39 and 49
months after transplantation, but tumor has recurred again
subsequently in both of these patients.
All patients achieved full rehabilitation and initial
good quality of life after the transplant procedure. Pul-
monary graft function has been good and stable (until the
development of recurrent BAC) except in 1 patient who
had bronchiolitis obliterans develop and has been treated
with OKT3, tacrolimus, and photophoresis. Figure 2
shows the Kaplan-Meier depiction of overall survival and
recurrence-free survival. Among the 8 patients with true
BAC, 3 deaths were of pulmonary failure related to
recurrent tumor in the transplanted lungs. The fourth
death occurred after retransplantation for recurrent tu-
mor. Two patients had postmortem examinations, and no
tumor was found in case 9. Case 5 had recurrent tumor in
the lung parenchyma but no regional or distant metasta-
sis.
Discussion
Compared with the natural history of diffuse BAC,3-5 com-
plete pulmonary resection and transplantation resulted in
improved survival and dramatic relief of severe dyspnea.
Survival in these patients was comparable to that of patients
undergoing lung transplantation for other types of end-stage
lung disease. Twenty-five percent of our patients with true
BAC had no apparent disease at 5 years. The main problem
in pursuing this treatment method is the high rate of tumor
recurrence. The mechanism of this is not understood, but the
available evidence seems to indicate that the tumor is the
same as the original lesions.7 Effective treatment for recur-
TABLE 2. Results of lung transplantation for BAC
Case Rejection and treatment Infection Survival* (mo) Status
Recurrence
Time† (mo) Treatment
1 A3 and A2, bolus steroids (2) None 89 Unrestricted 39 Left lower lobectomy
75 Wedge resection of right
middle and right lower
lobes
2 A2 2, bolus steroids (2) None 87 Unrestricted None
3 None None 82 Dead 49 Left lung,
pneumonectomy
68 Right lung, no treatment
4 None None 76 Unrestricted None
5 None Pneumonia,
Staphylococcus
aureus
and
Klebsiella
pneumoniae
33 Dead 12 Retransplantation
32 None
6 A2 3, bolus steroids (2),
bronchiolitis obliterans,
photophoresis
Cytomegalovirus 53 Severely
restricted
27 None
7‡ None None 38 Dead Cerebral metastasis,
chemotherapy, gamma
knife
Right rib metastasis, local
radiation
8 A2 2, bolus steroids (2) Herpes
zoster
15 Dead 10 None
9 A2 4, bolus steroids (4) CMV 21 Dead 9 Gene therapy
21 Retransplantation
*From date of transplantation; latest follow-up in cases of living patients.
†From date of transplantation.
‡Stage IV adenocarcinoma.
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rence has not been demonstrated. For those patients with
localized lesions, resection may be a temporizing strategy,
but its value is not established. No evidence of distant
metastasis has been seen in the patients with true BAC,
despite of long-term immunosuppression.
Our group stopped this study because of the high recur-
rence rate. A secondary reason was the increasing waiting
time for transplantation. No patients died while waiting for
transplantation, but several were desperately ill from pul-
monary failure before transplantation. In our view, an argu-
ment can be made for using bilateral lung transplantation
selectively for palliation in this disease if timely procure-
ment of donor lungs is possible.
Conclusions
In this small group of patients with BAC, 5-year survival
after standard lung transplantation was 52%. The deaths
were caused by pulmonary failure related to tumor recur-
rence in the lung allografts. The recurrence rate was 75% at
5 years. The mechanism of recurrence is not clear, and
effective treatment for it is not available. Most patients had
dramatic relief of their severe dyspnea and could return to
an active lifestyle. Transplantation for this indication re-
mains controversial.
We thank Dr John T. Carpenter for his advice regarding che-
motherapy and Robert N. Brown, BS, ChE, for his help with
Kaplan-Meier survival graphing.
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Figure 2. Survival and freedom from recurrence (Kaplan-Meier plot) after lung transplantation for 8 patients with
pathologically confirmed BAC and survival for total lung transplantation population during same period. UAB,
University of Alabama at Birmingham.
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